You’ve probably seen the numbers floating around Reddit threads and peptide forums. 250mcg twice daily. 500mcg once a day. Some people swear by 750mcg. Others claim you need to inject directly into the injury site, while another camp insists oral dosing works just fine.

So what’s the actual deal with BPC-157 dosage? And more importantly, does cranking up the dose give you better results?

Here’s the frustrating truth: we’re working with limited human data. Most of what we know comes from rodent studies, anecdotal reports, and a handful of small clinical trials. That doesn’t mean we’re flying completely blind, but it does mean you need to approach dosing recommendations with healthy skepticism.

Let’s break down what we actually know.

What the research tells us (and doesn’t)

BPC-157, short for Body Protection Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. The original research comes out of the University of Zagreb, where scientists have been studying this compound since the 1990s.

In animal studies, researchers typically use doses ranging from 10mcg/kg to 50mcg/kg of body weight. For a 180-pound (roughly 80kg) human, that translates to somewhere between 800mcg and 4,000mcg daily if you scale it directly.

But here’s where it gets tricky. You can’t just multiply rat doses by human weight and call it a day. Rodents metabolize compounds differently than we do. Their surface area to body weight ratio is different. What works in a mouse doesn’t always translate predictably to humans.

The few human trials that exist have looked at BPC-157 for inflammatory bowel conditions, using oral doses in the milligram range. We’re talking about different delivery methods and different therapeutic targets than what most peptide users are after.

The practical insight: Anyone who tells you there’s a scientifically proven optimal dose for injury healing in humans is overstating the evidence.

Where the common protocols come from

So if the science is fuzzy, why does everyone seem to land on similar numbers?

The 250-500mcg range that dominates online discussions appears to be an educated guess that’s been refined through collective experimentation. Early peptide users took the animal data, applied some conservative scaling, and started comparing notes.

Over time, certain patterns emerged. People reported benefits at these lower doses without obvious side effects. The numbers got repeated, shared, and eventually became the default starting point.

This is how a lot of peptide dosing works, honestly. It’s not ideal from a scientific standpoint, but it’s the reality we’re working with.

The typical protocols you’ll encounter look something like this:

Conservative approach: 200-250mcg once or twice daily Moderate approach: 250-300mcg twice daily (totaling 500-600mcg) Aggressive approach: 500mcg twice daily or higher

Most experienced users suggest starting at the lower end and adjusting based on your response. This makes sense from a risk management perspective. You can always increase, but you can’t un-take a dose.

The practical insight: These numbers aren’t carved in stone. They’re community-derived starting points, not clinically validated prescriptions.

Does location matter for injections?

This is where you’ll find heated debates. Some people insist you need to inject subcutaneously right next to your injured tendon or muscle. Others say it doesn’t matter because BPC-157 has systemic effects regardless of injection site.

The animal research offers some support for local administration. Studies looking at tendon and ligament healing often injected the compound directly into or near the damaged tissue. The thinking is that higher local concentrations might accelerate repair at that specific site.

But BPC-157 also appears to work through systemic mechanisms. It influences nitric oxide production, modulates growth hormone receptors, and affects blood vessel formation throughout the body. These aren’t purely local effects.

The compromise many users land on: inject somewhere in the general vicinity of the injury when practical, but don’t stress about hitting the exact spot. Subcutaneous injection in the abdominal area remains the most common approach for general use.

There’s also the oral route to consider. BPC-157 shows surprising stability in the digestive tract compared to most peptides. Some of the human trials used oral administration successfully. For gut-related issues specifically, oral dosing might actually make more sense.

The practical insight: Local injection probably doesn’t hurt, but systemic absorption likely matters more than precise placement for most applications.

Does more actually mean better?

Now for the question everyone really wants answered.

The dose-response relationship with BPC-157 doesn’t appear to be linear based on available evidence. In other words, doubling your dose probably won’t double your results.

Animal studies show significant effects at relatively modest doses. There’s a threshold you need to reach for the compound to work, but blasting past that threshold doesn’t seem to proportionally increase benefits. This pattern is common with signaling molecules and peptides in general.

Some users report that higher doses actually feel less effective or cause more side effects like fatigue or headaches. Whether this represents a real pharmacological ceiling or just individual variation is hard to say.

There’s also a practical consideration: BPC-157 isn’t cheap. Using twice as much product for marginally better results (if any) doesn’t make economic sense for most people.

The more interesting variable might be duration rather than dose. Consistent daily use over 4-8 weeks appears in most positive reports, regardless of the specific dose chosen. Tissue remodeling and healing take time. You’re not going to shortcut that process by megadosing.

The practical insight: Moderate, consistent dosing over several weeks likely beats aggressive short-term protocols.

Timing and cycling considerations

Should you split your dose? Take it all at once? Cycle on and off?

The half-life of BPC-157 isn’t precisely established in humans, but estimates suggest it’s relatively short, somewhere in the range of a few hours. This supports the logic of splitting doses to maintain more stable levels throughout the day.

Twice daily dosing (morning and evening) is the most common approach for this reason.

As for cycling, opinions vary. Some users take BPC-157 continuously until their issue resolves. Others prefer structured cycles, something like 4 weeks on followed by 2 weeks off. The cycling approach is partly based on general peptide principles (avoiding potential receptor downregulation) and partly on cost management.

There’s no strong evidence that BPC-157 causes tolerance or requires cycling. But there’s also no evidence that continuous long-term use is completely without consequence. When data is limited, building in breaks seems like reasonable caution.

The practical insight: Twice daily dosing makes pharmacological sense, and periodic breaks probably don’t hurt.

Putting it together

If you’re considering BPC-157, here’s a reasonable framework based on what we currently know:

Start with a conservative dose around 250mcg twice daily. Give it at least 2-3 weeks before evaluating effects. Tissue healing is slow, and you won’t see overnight results.

If you’re using it for a specific injury, injecting in the general area is reasonable but not mandatory. Subcutaneous administration in the abdomen works fine for systemic effects.

Don’t assume more is better. The jump from 500mcg total daily to 1000mcg or higher isn’t supported by proportionally better outcomes in user reports.

Consider cycling, especially for longer-term use. Something like 4-6 weeks on, followed by a break, gives your body time to respond and helps you evaluate what the peptide is actually doing versus placebo effect.

Pay attention to your body. Unusual fatigue, headaches, or digestive changes might signal you should back off the dose.

And finally, talk to a doctor who understands peptides if you have underlying health conditions. This is especially important if you’re dealing with a serious injury that might need conventional medical attention, or if you’re on other medications that could interact. “Wait and see if the peptide fixes it” is not a smart approach for injuries that show signs of infection, involve significant swelling, or aren’t improving over time.

The honest answer on BPC-157 dosage is that nobody knows the perfect number. What we have are reasonable starting points and a growing body of user experience to draw from. Start low, stay consistent, and adjust based on your own response.